Angiogenesis Imaging Using (68)Ga-RGD PET/CT: Therapeutic Implications.

Area of Science:

• Nuclear Medicine
• Molecular Imaging
• Oncology

Background:

• Angiogenesis imaging is crucial for diagnosing and treating malignant and nonmalignant diseases.
• The Arg-Gly-Asp (RGD) sequence targets αvβ3 integrin on angiogenic vessels and tumor cells.
• Radiolabeled RGD peptides are developed for angiogenesis imaging.

Purpose of the Study:

• To review the development and application of Gallium-68 (68Ga)-labeled RGD derivatives for angiogenesis imaging.
• To highlight the utility of 68Ga-RGD peptides in both preclinical and clinical settings.
• To explore their potential in assessing antiangiogenic treatments and theranostics.

Main Methods:

• Development of various radiolabeled Arg-Gly-Asp (RGD) peptide derivatives.
• Utilizing Gallium-68 (68Ga) as a radionuclide due to its favorable properties and generator availability.
• Application in preclinical and clinical studies for diverse diseases.

Main Results:

• 68Ga-labeled RGD derivatives have been extensively studied for angiogenesis imaging.
• Clinical trials covered malignant (breast cancer, glioma, lung cancer) and nonmalignant (myocardial infarction, atherosclerosis, moyamoya disease) conditions.
• These agents demonstrated potential in evaluating antiangiogenic therapy and theranostic applications.

Conclusions:

• Angiogenesis imaging with 68Ga-labeled RGD derivatives is a valuable tool.
• It aids in the development of new therapeutic assessments.
• It supports diagnostic and theranostic applications in oncology and other diseases.